SCHEMBL1007587

SCHEMBL1007587

CSc1sc(C(=O)NCCn2nc(C(F)(F)F)c3c2CCCC3)c2c1C(O)CCC2

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.47
ALDH1A1 P00352 2/20 0.46
HTT P42858 1/20 0.46
TSHR P16473 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 4/20 0.43
GAA P10253 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GRM1 Q13255 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 4/20 0.40
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007176 0.88 ALDH1A1 (0.52) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL1006668 0.83 TDP1 (0.47) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL1008127 0.82 ALDH1A1 (0.46) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL1007312 0.80 ALDH1A1 (0.44) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL1008032 0.80 ALDH1A1 (0.44) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL1007484 0.73 ALDH1A1 (0.65) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL12666937 0.73 TDP1 (0.45) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL12666935 0.73 TDP1 (0.45) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL12674203 0.71 TDP1 (0.43) ALDH1A1HTTTSHRTDP1LMNA
SCHEMBL12674154 0.71 TDP1 (0.43) ALDH1A1HTTTSHRTDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US claimed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP claimed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ADORA3 135/4885ALDH1A1 614/4885HTT 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.